JoVE Logo

Sign In

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.

Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without meddling with smooth muscle tone. These drugs considerably alleviate nasal congestion, persistent coughing, wheezing, and breathlessness upon inhalation. Their side effects include throat irritation, occasional coughing, and even fleeting wheezing and unsettling taste sensations. However, their relatively mild impact on inflammation and limited duration of effectiveness have limited their use in asthma management.

Anti-IgE treatments, including omalizumab (Xolair), present another innovative avenue for mitigating asthma's disruptive influence. These treatments work at a molecular level, targeting the IgE antibodies and preemptively inhibiting their interaction with mast cells, deterring degranulation of these cells, which in turn inhibits the allergic inflammatory cascade. Omalizumab is administered subcutaneously and lowers plasma IgE levels. It controls the severity of asthma and the frequency of its unwelcome exacerbations.

Omalizumab is an important addition to the treatment options for asthma. However, as with any intervention, it's not entirely devoid of possible side effects. Mild reactions at the injection site, encounters with viral infections, and the occasional upper respiratory tract infections have been reported. Also, the potential to cause anaphylactic reactions demands careful consideration and monitoring.

In the evolving landscape of asthma management, anti-inflammatory treatments like mast cell stabilizers and anti-IgE therapies emerge as vital players, offering respite to those grappling with the challenges of this intricate respiratory ailment.

From Chapter 19:

article

Now Playing

19.7 : Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Lower Respiratory Disorders

57 Views

article

19.1 : Asthma: Pathogenesis and Management

Lower Respiratory Disorders

78 Views

article

19.2 : Antiasthma Drugs: β2-Adrenoceptor Agonists

Lower Respiratory Disorders

58 Views

article

19.3 : Antiasthma Drugs: Methylxanthines

Lower Respiratory Disorders

42 Views

article

19.4 : Antiasthma Drugs: Leukotriene Modifiers

Lower Respiratory Disorders

75 Views

article

19.5 : Antiasthma Drugs: Muscarinic Receptor Antagonists

Lower Respiratory Disorders

44 Views

article

19.6 : Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Lower Respiratory Disorders

46 Views

article

19.8 : COPD: Pathogenesis and Clinical Features

Lower Respiratory Disorders

66 Views

article

19.9 : COPD: Management Using Bronchodilators and Corticosteroids

Lower Respiratory Disorders

42 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved